



- EU STREP Project -  
**Bloch electromagnetic surface  
wave biosensors  
for early cancer diagnosis**



# Project ID Card




- ▶ Funded under: EU 7<sup>th</sup> Seventh Framework Programme
- ▶ Topic: ICT 2011.3.5.a Core Photonic Technologies  
Subtopic (2) Biophotonics for early, fast and reliable medical diagnosis
- ▶ Reference: 318035
- ▶ Total cost: 4.73 M€
- ▶ EU contribution: 3.60 M€
- ▶ Start Date: October 1st 2012
- ▶ Duration: 36 months
- ▶ Contact: Prof. F.Michelotti (Project Coordinator )  
[francesco.michelotti@uniroma1.it](mailto:francesco.michelotti@uniroma1.it)

# Partnership

- ▶ Università degli Studi di Roma “La Sapienza”  
*Department of Basic and Applied Sciences for Engineering*
- ▶ Politecnico di Torino  
*Department of Applied Sciences and Technology*
- ▶ Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung
  - Unit a - IOF - Institut für Angewandte Optik und Feinmechanik*
  - Unit b - IWS - Institut für Werkstoff-und Strahltechnik*
- ▶ Imperial College London  
*Department of Materials*
- ▶ Università degli Studi di Torino  
*Department of Oncology*
- ▶ Labor, Srl
- ▶ Biotray, SAS
- ▶ Horiba Jobin Yvon, SAS
- ▶ KDS Radeberg, GmbH


# European Dimension



# Objectives

- ▶ Developing a compact and multifunctional point-of-care platform performing real-time cancer biomarker detection in a tandem label-free and fluorescence configuration.
- ▶ The bio-sensing platform will consist of:
  - Disposable and low cost dielectric 1D photonic crystal biochips
  - Reading device
- ▶ Validating at pre-clinical stage the platform by the detection at a very low concentration of Angiopoietins -1 and -2 which have been identified as tumor inducers.


# Concept



Properly designed 1DPC can sustain Bloch electromagnetic Surface Waves (BSW) at the interface, whose peculiar properties can be exploited for overcoming the limitations to sensitivity, selectivity, and resolution of present point-of-care cancer diagnostic tools and thus lead to a new class of advanced industrial products.

# Concept


Enhancement of the label-free operation performance




- $S=100^\circ/\text{RIU}$
- $W=1.7^\circ$
- $D=1$



**FOM=60 RIU<sup>-1</sup>**  
@ 804nm



$$\text{FOM} = S \times \frac{D}{W}$$



- $S=20^\circ/\text{RIU}$
- $W=0.02^\circ$
- $D=1$




**FOM=1000 RIU<sup>-1</sup>**  
@ 804nm


# Concept




## Enhancement of the fluorescence operation performance



Single  $\lambda$   
enhancement 560




Integral enhancement  
100



# Objectives

| Objective  | Target value  | Value of state of the art SPR platforms  |
|--|---|--|
| Sensitivity of amplitude-based sensors to refractive index changes | 30 RIU <sup>-1</sup>  | 150 RIU <sup>-1</sup>  |
| Resolution for refractive index changes                            | $\Delta n < 5 \cdot 10^{-8}$ RIU                            | $\Delta n \sim 2 \cdot 10^{-7}$ RIU  |
| Field enhancement factor for improving fluorescence intensity      | 5000  | 100  |
| Integration of label-free and enhanced fluorescence detection      | YES   | NOT EXISTING   |
| Resolution for detectable cancer biomarkers concentration          | 10ng/mL<br>(label-free)<br><br>$<0.1\text{ng/ml}$<br>(fluo) | 10ng/mL for Prostate Specific Antigen biomarkers<br><br>64 ng/mL for activated leukocyte cell adhesion molecule biomarkers |

# Workplan



# Exploitation potential



- ▶ The BILOBA platform represents a breakthrough in ultra-sensitive photonic systems for non invasive and point of care early diagnosis of cancer.
- ▶ BILOBA can potentially outperform conventional approaches and set a new standard for early recognition of malignancies.
- ▶ The increased performance of the BSW biochips will have a tremendous impact on the medical community, allowing cancer diagnosis at a very early stage with consequent increase of quality of life for the patients, increase of lifetime, and decrease of treatment costs.
- ▶ Horiba Jobin Yvon is leading the exploitation activities as it is well placed in the market which can directly exploit the BILOBA technology.

# Contact



SAPIENZA  
UNIVERSITÀ DI ROMA



**Francesco Michelotti**

[francesco.michelotti@uniroma1.it](mailto:francesco.michelotti@uniroma1.it)

**Emiliano Descrovi**

[emiliano.descrovi@polito.it](mailto:emiliano.descrovi@polito.it)



**Fraunhofer**

**Norbert Danz**

[norbert.danz@iof.fraunhofer.de](mailto:norbert.danz@iof.fraunhofer.de)

Imperial College  
London

**Molly Stevens**

[m.stevens@imperial.ac.uk](mailto:m.stevens@imperial.ac.uk)



**Federico Bussolino**

[federico.bussolino@irc.cnr.it](mailto:federico.bussolino@irc.cnr.it)



**Paolo De Stefanis**

[p.destefanis@labor-roma.it](mailto:p.destefanis@labor-roma.it)



**Raphael Anastase**

[r.anasthase@biotray.fr](mailto:r.anasthase@biotray.fr)

**HORIBA JOBIN YVON**

**Chiraz Frydman**

[chiraz.frydman@horiba.com](mailto:chiraz.frydman@horiba.com)

**KDS Radeberger**  
Präzisions-Formen- und Werkzeugbau GmbH

**Thomas Schubert**

[schubert@kds-werkzeugbau.de](mailto:schubert@kds-werkzeugbau.de)